Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
02 Octubre 2024 - 7:00AM
Business Wire
Logica®, an offering from Charles River
and Valo Health, will be leveraged to progress Lundbeck’s research
into disorders of the central nervous system
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize
Logica® to progress critical brain disease research.
“We are excited to partner with Lundbeck as they work toward the
discovery of novel treatments for neurodegenerative disease,” said
Professor Julie Frearson, Ph.D., Senior Vice President and Chief
Scientific Officer, Charles River. “Logica’s integrated,
AI-augmented process allows us to be an agile partner, and combined
with Lundbeck’s industry-leading neurology expertise, we look
forward to a successful collaboration.”
Logica is an Artificial Intelligence (AI) powered end-to-end
drug discovery solution that translates biological insights into
optimized preclinical candidates by leveraging the integration of
Valo Health’s AI-powered Opal Computational Platform™ and Charles
River’s leading expertise in drug discovery and preclinical
development. Through the agreement, Lundbeck will deploy Logica
with the aim of creating optimized small molecules that lead to
novel therapies for neurological research.
“To make a significant impact on neurological diseases today,
you need to be able to work on unprecedented molecular targets with
causal biology,” said Tarek Samad, Senior Vice President and Head
of Global Research at Lundbeck. “Partnering with Logica will allow
us to use a unique tool set, including AI-driven approaches, to
overcome drug design challenges which often slow down the
translation of promising targets into drug candidates.”
About Logica In 2022, Charles River and Valo Health
launched Logica, providing clients with transformed drug discovery
with a single integrated offering seamlessly translating targets to
candidate nomination under a partnering business model. Logica
utilizes industry-leading predictive models, chemical design, and
synthesis capabilities, DNA-encoded libraries, in silico high
throughput screening from Valo’s Opal Computational Platform as
well as Charles River’s leading capabilities in all aspects of
discovery optimization including high throughput screening,
medicinal chemistry, ADME, biology, pharmacology, and ultimately
safety testing and IND submission, joining together for the first
time to create a computation-powered, unified target-to-candidate
offering.
About Valo Health Valo Health, Inc is
a biotechnology company focused on utilizing large scale data
and AI-driven computation to discover and develop therapeutics.
Valo aims to fully integrate humancentric data across the entire
drug development life cycle into a single unified
architecture, thereby accelerating the discovery and development of
life-changing drugs while simultaneously reducing costs, time, and
failure rates. The company’s Opal Computational Platform™ is an
end-to-end drug discovery and development platform designed to
transform data into valuable insights that may accelerate
discoveries and enable Valo to advance a robust pipeline of
programs. Learn more about Valo by
visiting valohealth.com.
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241002073611/en/
Charles River Investor: Todd Spencer, Corporate Vice
President, Investor Relations 781.222.6455 todd.spencer@crl.com
Charles River Media: Amy Cianciaruso Corporate Vice
President & Chief Communications Officer +1-781-222-6168
amy.cianciaruso@crl.com
Valo Health Media: Olivia Offner
press@flagshippioneering.com
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
